Zai Lab (ZLAB) Projected to Post Earnings on Thursday

Zai Lab (NASDAQ:ZLAB - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.33) per share and revenue of $118.40 million for the quarter. Zai Lab has set its FY 2025 guidance at EPS.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million during the quarter, compared to analysts' expectations of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Stock Performance

NASDAQ:ZLAB traded down $1.09 during trading hours on Tuesday, reaching $29.86. The company's stock had a trading volume of 344,868 shares, compared to its average volume of 1,071,171. The firm has a 50-day simple moving average of $33.12 and a 200-day simple moving average of $29.77. Zai Lab has a 1 year low of $16.01 and a 1 year high of $39.77. The firm has a market capitalization of $3.29 billion, a price-to-earnings ratio of -10.78 and a beta of 1.04.

Insider Buying and Selling

In other news, insider Rafael Amado sold 3,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $38.41, for a total value of $115,230.00. Following the completion of the transaction, the insider now owns 30,834 shares of the company's stock, valued at approximately $1,184,333.94. This represents a 8.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Frazor Titus Edmondson III sold 14,544 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $32.98, for a total value of $479,661.12. Following the completion of the transaction, the insider now owns 14,328 shares of the company's stock, valued at approximately $472,537.44. The trade was a 50.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 138,744 shares of company stock valued at $4,685,294 over the last quarter. 13.88% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. boosted their target price on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, March 13th. Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. Scotiabank assumed coverage on shares of Zai Lab in a report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price target for the company. Finally, Bank of America reissued a "neutral" rating and issued a $36.10 price target (up previously from $29.00) on shares of Zai Lab in a report on Monday, March 3rd.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.